Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

Johnson & Johnson MedTech today announced its sponsorship of a new PFA data collection platform from the Heart Rhythm Society ...

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

Catheter ablation significantly reduces cardiovascular risks and mortality in patients with both atrial fibrillation and obstructive sleep apnea. The study involved over 18,000 patients, showing a ...

The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for patients with atrial fibrillation (AFib). The approval follows earlier CE ...

CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly ...

NEW ORLEANS -- The diabetes drug metformin reduced recurrent arrhythmias after a first catheter ablation procedure for atrial fibrillation (Afib) in patients with overweight or obesity but without ...

Share on Pinterest A new study found that ablation is an effective treatment for AFib in most patients. VICTOR TORRES/Stocksy A recent study investigates how well radiofrequency-based ablation treats ...

BOSTON -- Pulsed field ablation (PFA) trials continued to accrue positive data, as reported at the Heart Rhythm Society (HRS) annual meeting. Secondary analysis of the pivotal ADVENT trial showed that ...

Obstructive sleep apnea and atrial fibrillation (AFib) are two conditions that share a potentially deadly link. Having one increases the odds of developing the other, and together, the breathing ...